Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>In silico</i> characterization of MC4R variants reveals insights into Setmelanotide pharmacogenomics and personalized medicine for obesity.

Personalized medicine·2026
Same author

Preclinical Evaluation of the Methyl (Z)-2-(isothioureidomethyl)-2-pentenoate Hydrobromide: Antitumor Efficacy and Safety Profile in a Murine Melanoma Model.

Anti-cancer agents in medicinal chemistry·2026
Same author

The anti‑inflammatory activity of 2‑iminothiazolidines: the role of PPARγ and M2 macrophage subpopulations.

Inflammopharmacology·2026
Same author

2,2,2-Tri-fluoro-ethyl 5-methyl-1<i>H</i>-pyrazole-3-carboxyl-ate.

IUCrData·2026
Same author

MicroRNAs as Key Regulators in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Bioinformatics Analysis.

Biomedicines·2026
Same author

Calcium phosphate nanoparticles efficiently deliver miR-205-5p to modulate oncogenic targets in prostate cancer cells.

International journal of pharmaceutics·2025

Related Experiment Video

Updated: Apr 20, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.3K

Isothiouronium salts reduce NRAS expression, induce apoptosis and decrease invasion of melanoma cells.

Julia Cisilotto, Misael Ferreira, Fabiola Branco Filippin-Monteiro

  • 1Departamento de Ciencias Farmaceuticas, Universidade Federal de Santa Catarina, 88040-900 Florianopolis, SC, Brazil. tania.pasa@ufsc.br.

Anti-Cancer Agents in Medicinal Chemistry
|December 4, 2014
PubMed
Summary

New isothiouronium salts show promise against melanoma. Compound 1 reduced NRAS expression, increased cell death, and synergized with vemurafenib, warranting further pre-clinical study.

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.6K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

3.0K

Related Experiment Videos

Last Updated: Apr 20, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

19.3K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.6K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

3.0K

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Molecular Biology

Background:

  • Melanoma is an aggressive skin cancer often driven by BRAF and NRAS mutations.
  • Current treatments like vemurafenib face challenges due to resistance and side effects.
  • There is an urgent need for novel antimelanoma agents.

Purpose of the Study:

  • To evaluate the antimelanoma potential of novel allylic isothiouronium and isothiosemicarbazide salts.
  • To investigate their effects on cell viability, cell cycle, apoptosis, and metastasis.
  • To assess their synergistic effects when combined with vemurafenib.

Main Methods:

  • Viability, cell cycle, apoptosis, migration, and invasion assays were performed on melanoma cell lines.
  • NRAS and BRAF expression levels were analyzed.
  • Compounds were tested alone and in combination with vemurafenib.

Main Results:

  • Isothiouronium salts 1-3 demonstrated significant antimelanoma activity with CC50 values between 7-28 μM.
  • Compound 1 reduced NRAS expression and induced apoptosis without affecting cell cycle progression.
  • Compounds 1 and 2 inhibited melanoma cell migration and invasion.
  • Combination therapy with vemurafenib showed synergistic effects, significantly reducing cell viability.

Conclusions:

  • Allylic isothiouronium salts, particularly compound 1, exhibit promising antimelanoma properties.
  • Compound 1's ability to reduce NRAS expression and induce apoptosis, along with its synergistic effect with vemurafenib, makes it a strong candidate for pre-clinical development.
  • These novel compounds represent a potential new therapeutic strategy for melanoma treatment.